strong quarter still watch
sign demand elast
deliv much better-than-expect result
meaning nitpick quarter highlight revenu growth y/i
ex-fx come forecast consensu remind
view expect come earn conserv compani guid
revenu q/q consensu park
major beat driven servic revenu microarray busi
grew respect sequenc revenu grew solid y/i
beat forecast novaseq placement sequenti
expect manag reiter forecast placement
upgrad cycl span multipl year consum revenu grew
y/i rel easi comp top-lin beat drove signific
ebit beat vs forecast much top-lin beat flow ebit
manag discuss ramp invest sale throughout year
adj ep beat forecast street
even exclud one-tim tax benefit relat helix adjust ep beat
forecast
said remain valuat sensit get better visibl
novaseq cycl impact elast demand custom clearli illumina
lot momentum back healthi end market fund domin
posit research custom burgeon opportun clinic
set continu expect substanti transit instal base
toward novaseq next sever year elast demand critic
compani drive price point sequenc continu
believ earli tell rate custom decommiss instrument
rate spend revenu platform elast demand
critic justifi long-term earn trajectori busi justifi
valuat last night close share trade new ep
forecast almost revenu forecast billion
reiter equal weight rate rais pt
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight leader next
gener sequenc market
project substanti long-term growth clinic
opportun posit
fundament impress
compani abil transform genom market
believ sentiment well reflect share
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ebitda billion
given pace innov cycl next
gener sequenc believ still
earli declar instrument choic
clinic use downsid case reflect
downsid ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
deliv much better-than-expect result meaning
nitpick quarter highlight revenu growth y/i ex-fx
come forecast consensu remind view expect
come earn conserv compani guid revenu
q/q consensu park major beat
driven servic revenu microarray busi grew
respect sequenc revenu grew solid y/i beat forecast
novaseq placement sequenti expect manag reiter
forecast placement upgrad cycl span multipl
year consum revenu grew y/i rel easi comp
top-lin beat drove signific ebit beat vs forecast much top line beat
flow ebit manag discuss ramp invest sale
throughout year adj ep beat forecast street
even exclud one-tim tax benefit relat helix adjust ep
beat forecast
said remain valuat sensit get better visibl
novaseq cycl impact elast demand custom clearli illumina lot
momentum back healthi end market fund domin posit
research custom burgeon opportun clinic set illumina
continu expect substanti transit instal base toward novaseq
next sever year elast demand critic compani drive
price point sequenc continu believ earli tell rate
custom decommiss instrument rate spend revenu
platform elast demand critic justifi long-term earn
trajectori busi justifi valuat last night close illumina
share trade new ep forecast almost revenu
forecast billion reiter equal weight rate
rais price target reflect strong start
price target repres ebitda billion prior price target
repres prior ebitda forecast billion
follow strong result rais revenu ep guidanc
compani expect revenu growth rang prior
guidanc growth increas revenu guidanc driven stronger
expect sequenc consum addit compani embed
mileston relat payment associ recent loxo oncolog bristol-my
squibb collabor consist previou guidanc expect place
novaseq non-gaap ep expect rang
midpoint prior guidanc midpoint ep guidanc repres
growth y/i ep guidanc includ dilut helix addit
embed guidanc assumpt gross margin expand slightli
given strong busi momentum decid make increment
commerci invest result compani expect non-gaap oper expens
flat slightli percentag revenu follow tax benefit
helix invest anticip non-gaap tax rate
compani expect share count million
expect modest sequenti revenu growth emb growth
sequenc consum instrument partial off-set season declin
microarray gross margin expect declin sequenti driven mix
higher cost associ new pharma collabor oper expens
percentag revenu expect line
provid novaseq placement compani said
placement sequenti line expect expect
compani place instrument bring cumul number novaseq
placement exclud million stock order novaseq
consum grew roughli sequenti demand driven strength
compani flow cell feedback recent flow cell launch
posit also continu confid novaseq expand
whole-genom sequenc market custom quarter either new
upgrad compani benchtop sequenc platform compani
still believ earli stage replac cycl
approxim high throughput custom adopt novaseq
regard futur ceo desouza note compani continu expect
place novaseq
model forecast novaseq placement averag
consum pull-through follow expect placement
assum novaseq place repres
replac least one hiseq compani start see cannib hiseq
 custom well given rel advantag novaseq forecast
million novaseq revenu year launch compar
million nextseq revenu million hiseq revenu year
guidanc growth gross marginup modestli slightli y/ynon-gaap op base per sharenon-gaap interest extinguish debtleg contingenciescost-method investmentsconting compensationheadquart relocationothergaap barclay illumina inc
market clearli show great enthusiasm prospect novaseq
said continu debat around capac constraint upper end
sequenc market face headwind high-throughput
sequenc market impact sale hiseq line sequenc manifest
lower instrument sale well lower consum pull-through
hiseq versu prior rang introduct
novaseq offer cost qualiti ease-of-us turnaround advantag custom
compani believ drive price point sequenc expand market
said launch inher differ prior launch given
rel matur compani custom note consum growth
moder follow growth growth year
prior
new product launch import drive top-lin growth increas
sequenc demand analyz success last major new product cycl
hiseq nextseq introduct found strong
product launch begin carri compani
busi line grown modestli specif
competitor industri confer introduc hiseq nextseq
follow launch estim product contribut million
revenu place hiseq instrument million
nextseq system lead overal revenu growth momentum remain
strong leverag instal base higher consum growth
believ factor contribut signific interest launch
hiseq view game-chang whole-genom sequenc push price
point sequenc nextseq fill gap portfolio
first major product launch two year hiseq
hiseq nextseq meaning contributor overal revenu growth
sinc launch novaseq help improv visibl
specif estim hiseq nextseq product contribut
revenu growth balanc illumina
portfolio seen modest revenu growth
look portfolio similarli hiseq nextseq
workhors growth rate estim balanc illumina portfolio
miniseq miseq hiseq actual declin
illumina revenu contribut novaseq hiseq nextseq
follow new product updat industri confer start
one top question receiv sustain driver
consum growth compani elast demand one top debat
compani drive expand competit advantag drive
price sequenc also risk cannib compani revenu
lower price point believ price continu annual headwind illumina
innov drive price per gb sequenc launch hiseq
expand whole genom market significantli also greatli reduc
price sequenc give sens launch hiseq significantli
reduc price per gb sequenc hiseq famili platform
hiseq
expect similar step-down play sequenc transit hiseq
custom toward novaseq launch novaseq sequenc platform
custom focus whole-genom sequenc speed throughput advantag
rel legaci hiseq hiseq product line estim price per gb
sequenc novaseq current though anticip innov
ultim drive price lower time estim per gb illumina
highlight hiseq custom adopt novaseq
custom oper approxim hiseq instrument end
compani believ hiseq hiseq custom eventu transit
novaseq estim novaseq order custom
either new upgrad compani desktop sequenc platform
import continu monitor level adopt new custom
consum growth deceler past two year believ
import show inflect show elast outweigh
price reduct post consum growth
year prior recent year cost sequenc
decreas introduct hiseq recent novaseq
believ volum sequenc continu increas believ downward
pressur price sequenc serv headwind consum
growth model consum growth repres modest
improv ramp-up novaseq instal base well easi comp
posit higher expect sequenc pull-through could provid lever
increment volum growth model pull-through theoret
maximum around million per instrument per flow cell run everi day
novaseq certainli util workhors identifi custom
util level expect meaning lower said work
transit novaseq without correspond uptick demand elast
compani would cannib work lower price point model
consum growth slow
specif novaseq model pull-through per instrument expect
placement grow model uptick gb
sequenc year novaseq launch off-set price reduct
work transit hiseq novaseq
analysi consum growth price vs gb sequenc
order recent launch iseq platform approach
compani expect scale shipment mid-year follow custom beta test
compani identifi opportun improv cartridg fill ship
process improv expect improv product robust
reliabl background announc iseq launch januari
expand portfolio breadth lower-throughput end sequenc market
view instrument nice addit portfolio though addit
growth vs high-throughput platform compani describ iseq inexpens
fast easi use sequenc iseq util best-in-bre sequenc
synthesi sb chemistri coupl complementari metal-oxide-semiconductor
cmo detect technolog iseq target address market
potenti custom rang current owner new-to- custom iseq
gener million read greater per run run-tim rang
hour price per sampl rang addit
sequenc cost less instal custom less one hour
addit iseq launch announc partnership thermo fisher
allow compani commerci thermo fisher ion ampliseq
technolog research custom ceo franci desouza note break-out
session agreement stem mutual understand two
compani thermo fisher develop best-in-class amplicon technolog allow
effect captur dna rna small amount sampl thermo fisher
provid ion ampliseq technolog distribut directli
custom name ampliseq agreement preclud
thermo fisher sell ampliseq technolog current new sequenc
custom believ agreement commend show illumina
willing partner best-in-class product even mean partner
major competitor thermo fisher give compani new revenu growth
access sizabl instal base
continu wrestl right valuat recommend invest
compani clear market leader next-gener sequenc
fastest grow market life scienc tool technolog opinion matter
way diagnost market move genom expect play critic role
backbon innov addit compani invest thesi cater
well wide array investor base healthcar technolog even consum
audienc growth perspect look outsid life scienc tool
coverag find compani similar profil chart weve
analyz six large-cap internet name make interest set peer given size
growth trajectori interestingli trade doubl sale
multipl internet compar compani tripl multipl
look ev sale growth
thomson one consensu data compani
note price
note price
revenu grew y/i million expect rel
expect better-than-expect demand sequenc array
consum drove revenu beat geograph perspect growth
broad-bas quarter growth unit state growth emea
growth asia-pacif region specif shipment china
strength america emea result demand sequenc instrument
revenu y/i growth
revenu growth geographi
gener revenu consum driven
strength array consum look back increas instal
base instrument market consum pull follow servic revenu
revenu grew y/i due mainten contract larger instal base
genotyp servic consum demand
mix revenu instrument vs recur
revenu increas y/i million total revenu
consum grew quarter specif strength high throughput
analyz growth novaseq primari driver consum growth
quarter grow sequenti exclud million stock order
strong growth flow cell nextseq util came high
end guid rang believ miseq pull fell within
rang set pull-through guidanc rang miniseq
manag commentari impli util fell within rang
given on-going novaseq upgrad cycl hiseq hiseq consum decreas
million sequenti quarter instrument revenu improv y/i
servic revenu also strong quarter grow y/i
novaseq high throughput sequenc platform custom focus whole-
genom sequenc advantag rel legaci hiseq hiseq product
line instal base hiseq hiseq instrument compani
address larg market opportun base instrument sale alon upsid
would driven market expans drive higher consum revenu
said placement cannib exist instrument consum opportun
would limit note consum cost per sampl like go
applic mean consum revenu could actual declin
per-box basi view launch make sens revolutionari
product aim drive replac cycl put rest concern
around revenu visibl near term long-term overcapac concern
like remain compani tri expand market beyond current instal
design system larg market opportun mind note
system allow highest-throughput achiev lower sequenc cost
much lower capit commit rel hiseq hiseq
company/systemlaunchedinstru costrun costrun lengthrun speedthroughputpric per gbilluminaiseq fisher life ion day all-in n/an/abgi complet genomicsrevoloc ii long nanopor barclay illumina inc
compani believ architectur novaseq platform eventu
allow achiev genom system use newli develop
flow cell allow higher-throughput increas speed-to-result
maintain accuraci earlier system compani launch novaseq
three flow cell option three flow cell throughout
capabl hiseq respect modestli
reduc speed-to-result hiseq day day novaseq
price capabl run three flow cell earn
announc cancel novaseq flow cell
custom primarili demand novaseq instrument
hiseq anticip demand hiseq weaker quarter custom
opt novaseq platform importantli focus convert
exist hiseq custom novaseq remind hiseq launch
per system januari announc launch
hiseq enhanc leverag capabl hiseq
system hiseq price reagent price per gb
similarli hiseq price provid half output lower
reagent costs/fast run time base commentari assum util
low end compani guid rang per instrument
hiseq consum expect trend downward throughout
hiseq launch novaseq plan drive replac cycl
hiseq custom come year launch hiseq
sequenc whole human genom compani market product
 sell ten instrument increas throughput larg genom center
reach covet genom price system million
note hiseq consum revenu declin million sequenti
quarter larg driven hiseq custom expect signific
replac cycl instrument follow recent launch flow cell
said compani note number custom need finish current
project upgrad
januari announc sell hiseq five system
configur known hiseq hiseq allow product center
adopt high-throughput whole genom sequenc lower capit invest
 full util set-up estim sequenc
genom year compani sell hiseq system million
addit hiseq xs million thereaft sequenc cost per gb
approxim versu hiseq
nextseq launch nextseq system fill nich product
portfolio hiseq miseq instrument product flex whole
human genom sequenc target panel price per system
estim compani place nextseq global pull-through
high end guid rang strength
also launch nextseq combin microarray scan
nextseq sequenc system initi array qualifi system
cytogenet pgd applic expect enabl broad rang
applic reproduct health genet health oncolog adapt
allow lab gain access array sequenc singl capital-expenditure
revenu growth
miseq miseq util fell within compani guid rang quarter sinc
launch miniseq encourag lower expect level
miseq cannib ultim believ market desktop
instrument minimum estim place though
could make argument market size product price
unit expect annual pull-through
miniseq/iseq launch januari miniseq compani smallest
benchtop sequenc design target sequenc applic smaller lab
cost instrument roughli believ pull number
quarter rang earli januari announc iseq
launch expand portfolio breadth lower-throughput end
sequenc market compani describ iseq inexpens fast easi
use sequenc iseq target address market potenti custom
rang current owner new-to- custom model current
instal base miniseq iseq instrument
array revenu increas y/i quarter million strength driven
primarili consum servic respect instrument
growth also solid quarter remain smaller million
similarli recent trend demand driven strength direct-to-consum
market remind provid in-hous test servic dtc test
compani notabl ancestrydna compani also supplier dtc compani
run volum in-hous partner laboratori
gross margin improv y/i driven posit mix strength consum
easier comp compani non-gaap gross margin y/i
gross margin expect modestli keep mind
better margin consum revenu grew y/i revenu outpac
instrument growth y/i servic growth ebitda margin
y/i
 declin y/i revenu ex-comp sg ex-comp
decreas y/i revenu result top line leverag total oper
expens sg stock-bas comp declin y/i revenu
helix account sg percentag revenu
non-gaap sg revenu
non-gaap ep increas y/i compani leverag strong top
line perform y/i margin improv deliv solid earn growth
benefit tax benefit particip recent helix
seri financ round asid tax benefit compani impact
helix dilut flat q/q addit fx provid tailwind non-gaap ep
quarter
marginadj revenu dsg barclay illumina inc
quarterli non-gaap ep y/i growth
y/i growthnon-gaap epsepsy/i growthillumina except ep reportedincom profit base ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
